Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PHKA1 antisense RNA 1 (PHKA1-AS1) is a long noncoding RNA (lncRNA) arising as a natural antisense transcript to the *PHKA1* gene. It consists of 599 base pairs and lacks protein-coding potential. PHKA1-AS1 is upregulated in non-small cell lung cancer (NSCLC), where increased N6-methyladenosine (m6A) modification stabilizes it. In cancer, PHKA1-AS1 promotes cell proliferation, migration, and metastasis by binding to actinin alpha 4 (ACTN4)—an oncogenic protein—and suppressing its ubiquitin-mediated degradation, thus enhancing ACTN4 protein stability. Inhibition of PHKA1-AS1 reverses these pro-tumorigenic effects. PHKA1-AS1 is studied as a potential biomarker of tumor progression, particularly in NSCLC, but is not itself a therapeutic target, receptor, enzyme, or transporter[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PHKA1 antisense RNA 1 (PHKA1-AS1).